Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

• Published in: ACS combinatorial science Vol. 22; no. 12; pp. 669 - 700
• Main Authors: Ashrafizadeh, Milad, Zarrabi, Ali, Hushmandi, Kiavash, Hashemi, Farid, Rahmani Moghadam, Ebrahim, Raei, Mehdi, Kalantari, Mahshad, Tavakol, Shima, Mohammadinejad, Reza, Najafi, Masoud, Tay, Franklin R, Makvandi, Pooyan
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 14.12.2020
• Subjects: Review; anticancer therapy; co-delivery platforms; natural products; small interfering RNA; chemotherapy; nanocarriers
• ISSN: 2156-8952; 2156-8944; 2156-8944
• DOI: 10.1021/acscombsci.0c00099

Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, co-delivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research.